Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
PR Newswire•31/08/2026•06:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.